News OEM

Supporting your immunoassay portfolio expansion

Biomaterials for IGFBP-3 immunoassay development & manufacturing

January 22, 2025

Scientist with columns

 

Biomaterials for IGFBP-3 immunoassay development & manufacturing

Insulin Growth Factor Binding Protein 3 (IGFBP-3) is a protein found in circulation and inside cells. It is composed of 264 amino acids and has a molecular weight ranging from 28.7 kDa to 53 kDa[1]. IGFBP-3 belongs to the family of insulin growth factor binding proteins, which includes six major types, from IGFBP-1 to IGFBP-6. The expression of both IGFBP-3 and IGF-1 is stimulated by growth hormone (GH), which encompasses the secretion of IGF-1 to circulation and its binding with IGFBP-3[2].

IGFBP-3 is the most prevalent type in human adult serum and is primarily produced in the liver and other peripheral tissues before being secreted into the bloodstream[2]. IGFBP-3 binds mainly to insulin growth factors (IGFs), acting as a transport protein. It prolongs the half-life of IGFs and regulates their removal from circulation[3].

In clinical laboratory, serum levels of IGFBP-3 are considered useful aid in the diagnosis and monitoring of growth-hormone related clinical conditions like acromegaly and growth hormone deficiency [4].

 

How Werfen can support you

We can support your immunoassay portfolio expansion in the endocrinology panel by providing specifically designed antibodies to detect IGFBP-3.

Werfen endocrinology portfolio consist of the following products. 
 

Biomaterial

PN

Product Description

Antibody

3000-7076Anti-IGFBP-3 mAb (BP371m)
3000-7077Anti-IGFBP-3 mAb (BP324m)
3000-5316Anti-hGH mAb (7)
3000-5319Anti-hGH mAb (5)
3000-5315Anti-Cortisol mAb (3)
3000-5318Anti-Cortisol mAb (4)
3421-0000Anti-Prolactin mAb (1)
3421-0001Anti-Prolactin mAb (2)

[1] Rajaram et al. Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions. Endocrine Reviews. 1997

[2] Allard J et al. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?  Frontiers in Endocrinology. 2018

[3] Haywood et al The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes. Molecular Metabolism. 2019

[4] Bidlingmaier et al. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Archives of Endocrinology and Metabolism. 2019


 

Share Press Release:

LinkedIn twitter facebook
Contact us

Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

DATA PROTECTION POLICY:

Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at DPO-biokit@werfen.com.